Pregabalin Sandoz GmbH
Active Substance: pregabalin
Common Name: pregabalin
ATC Code: N03AX16
Marketing Authorisation Holder: Sandoz GmbH
Active Substance: pregabalin
Authorisation Date: 2015-06-19
Therapeutic Area: Epilepsy Anxiety Disorders
Pharmacotherapeutic Group: Antiepileptics
Pregabalin Sandoz GmbH is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Generalised Anxiety Disorder
Pregabalin Sandoz GmbH is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
What is Pregabalin Sandoz GmbH and what is it used for?
Pregabalin Sandoz GmbH is a medicine used to treat adults with the following conditions:
- epilepsy, where it is used as an ‘add-on’ to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
Pregabalin Sandoz GmbH is a ‘generic medicine’. This means that Pregabalin Sandoz GmbH is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Lyrica.
Pregabalin Sandoz GmbH contains the active substance pregabalin.
How is Pregabalin Sandoz GmbH used?
Pregabalin Sandoz GmbH is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. The recommended starting dose is 150 mg per day, divided into two or three doses. After three to seven days, the dose can be increased to 300 mg per day. Doses can be increased up to twice more until the most effective dose is reached. The maximum dose is 600 mg per day. Stopping treatment with Pregabalin Sandoz GmbH should also be done gradually, over at least a week. Doctors may need to lower the dose in patients who have kidney problems.
How does Pregabalin Sandoz GmbH work?
The active substance in Pregabalin Sandoz GmbH, pregabalin, is similar in structure to the body’s own ‘neurotransmitter’ gamma‑amino butyric acid (GABA), but has very different biological effects. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The exact way that pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.
How has Pregabalin Sandoz GmbH been studied?
Because Pregabalin Sandoz GmbH is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
What are the benefits and risks of Pregabalin Sandoz GmbH?
Because Pregabalin Sandoz GmbH is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Why is Pregabalin Sandoz GmbH approved?
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz GmbH has been shown to have comparable quality and to be bioequivalent to Lyrica. Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk. The Committee recommended that Pregabalin Sandoz GmbH be approved for use in the EU.
What measures are being taken to ensure the safe and effective use of Pregabalin Sandoz GmbH?
A risk management plan has been developed to ensure that Pregabalin Sandoz GmbH is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Sandoz GmbH, including the appropriate precautions to be followed by healthcare professionals and patients.
Further information can be found in the summary of the risk management plan.
Other information about Pregabalin Sandoz GmbH
The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Sandoz GmbH on 19 June 2015.
For more information about treatment with Pregabalin Sandoz GmbH, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.